CGEM - Cullinan Oncology LLC - Stock & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2300311063

Cancer, Antibodies, Therapies

Cullinan Oncology LLC, a pioneering biopharmaceutical company, is dedicated to developing innovative oncology therapies to improve the lives of cancer patients in the United States.

The company's lead program, CLN-619, is a monoclonal antibody currently in Phase I clinical trial, aiming to combat solid tumors. This cutting-edge treatment has the potential to revolutionize the way we approach cancer treatment.

Additionally, Cullinan Oncology's development portfolio boasts an impressive range of promising therapies. CLN-049, a humanized bispecific antibody, is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndrome. CLN-418, a human bispecific immune activator, is being tested in Phase 1 clinical trial for the treatment of multiple solid tumors.

Zipalertinib, a bioavailable small-molecule, is being developed to treat patients with non-small cell lung cancer. Furthermore, the company's development pipeline includes CLN-617, a fusion protein for the treatment of solid tumors, and CLN-978, a T cell engaging antibody for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.

Cullinan Oncology has formed strategic partnerships to accelerate its mission. The company has a license and collaboration agreement with Adimab, LLC to discover and optimize antibodies. It has also partnered with Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418. Moreover, Cullinan Oncology has a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib.

Formerly known as Cullinan Oncology, Inc., the company changed its name to Cullinan Therapeutics, Inc. in April 2024. Founded in 2016, Cullinan Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, and is committed to pushing the boundaries of cancer treatment. To learn more, visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for CGEM - Cullinan Oncology LLC  - Stock & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for CGEM - Cullinan Oncology LLC  - Stock & Dividends

CGEM Stock Overview

Market Cap in USD 930m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2021-01-08

CGEM Stock Ratings

Growth 5y -23.3
Fundamental -70.1
Dividend 0.00
Rel. Performance vs Sector 2.85
Analysts 4.78/5
Fair Price Momentum 20.82 USD
Fair Price DCF -

CGEM Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

CGEM Growth Ratios

Growth 12m 74.69%
Growth Correlation 12m 47%
Growth Correlation 3m -54%
CAGR 5y -12.99%
CAGR/Mean DD 5y -0.20
Sharpe Ratio 12m 0.98
Alpha vs SP500 12m 47.57
Beta vs SP500 5y weekly 1.23
ValueRay RSI 56.93
Volatility GJR Garch 1y 64.84%
Price / SMA 50 -11.34%
Price / SMA 200 19.08%
Current Volume 482.1k
Average Volume 20d 914.8k

External Links for CGEM Stock

Wall Street JournalBenzingaYahoo Finance
Fund Manager Positions
What is the price of CGEM stocks?
As of July 21, 2024, the stock is trading at USD 18.29 with a total of 482,052 shares traded.
Over the past week, the price has changed by +11.19%, over one month by +4.45%, over three months by +16.79% and over the past year by +77.23%.
What are the forecast for CGEM stock price target?
According to ValueRays Forecast Model, CGEM Cullinan Oncology LLC will be worth about 23.3 in July 2025. The stock is currently trading at 18.29. This means that the stock has a potential upside of +27.34%.
Issuer Forecast Upside
Wallstreet Target Price 33 80.4
Analysts Target Price 24.6 34.5
ValueRay Target Price 23.3 27.3